TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
Ontology highlight
ABSTRACT: Liver metastases are a leading cause of death among patients with metastatic colorectal cancer. Duration of disease control is short following 2nd-line or later systemic therapy. Liver-directed therapy such as TACE has a higher response rate and improves progression-free survival (PFS), but the benefit is still limited. Cancer cells escape ischemic cell death via autophagy and hypoxia-inducible factor (HIF) activation. We hypothesize that blocking autophagy and the vascular endothelial growth factor (VEGF) pathway will improve both response and PFS following TACE.
DISEASE(S): Colorectal Neoplasms Malignant,Colorectal Cancer,Colorectal Neoplasms,Neoplasms
PROVIDER: 2376535 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA